INTENSIVE THERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AND UNFAVOURABLE PRESENTING FEATURES
β Scribed by Gaynon, PaulS.; Bleyer, W.Archie; Albo, VincentC.; Grossman, NeilJ.; Novak, LouisT.; Reaman, GregoryH.; Steinherz, PeterG.; Ablin, ArthurR.; Finklestein, JerryZ.; Littman, PhilipS.; Pyesmany, AllanF.; Sather, HarlandN.; Hammond, G.Denman
- Book ID
- 122037663
- Publisher
- The Lancet
- Year
- 1988
- Tongue
- English
- Weight
- 553 KB
- Volume
- 332
- Category
- Article
- ISSN
- 0140-6736
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract The percent of marrow blasts on day 7 of therapy was determined for 128 children with previously untreated acute lymphoblastic leukemia and white blood count (WBC) Β± 50,000/ΞΌl and/or lymphomatous features enrolled in the Childrens Cancer Study Group trial of the Berlin Frankfurt Munster
Dose and dose intensity are believed critical for attaining a maximal therapeutic effect in drug-responsive tumor systems. Childhood acute lymphoblastic leukemia may be an example of such a drug-responsive system as it is cured with current chemotherapy in a majority of cases. Between August 1981 an